Skip to main content

Table 1 Sociodemographic and clinical characteristics of the 107 patients with PXE.

From: The relative impact of vision impairment and cardiovascular disease on quality of life: the example of pseudoxanthoma elasticum

  Total sample (n = 107) Group A (n = 16)
No VI or CVCs
Group B (n = 35)
Only CVCs
Group C (n = 15)
Only VI
Group D (n = 41)
VI & CVCs
p value*
n (%)       
Gender       0.917
   Male 38 (36%) 5 (31%) 14 (40%) 4 (27%) 15 (37%)  
   Female 68 (64%) 11 (69%) 21 (60%) 10 (67%) 26 (63%)  
Help to fill in questionnaires (self-report) 45 (42%) 1 (6%) 3 (9%) 9 (60%) 32 (78%) < 0.001
Mean ± SD       
Age (years) 57 ± 12 47 ± 11 53 ± 10 54 ± 16 64 ± 9 < 0.001
BCVA Snellen (LogMAR) 20/125 (0.79 ± 0.67) 20/25 (0.11 ± 0.11) 20/32 (0.16 ± 0.16) 20/250 (1.10 ± .056) 20/320 (1.24 ± 0.53) < 0.001
Average no. of CVCs 1.61 ± 1.39 0 2.09 ± 1.12 0 2.41 ± 1.07 < 0.001
Duration of PXE (years) 17 ± 12 11 ± 10 18 ± 13 20 ± 14 18 ± 9 0.127
Functional IVI score 20.16 ± 8.16 28.12 ± 4.99 23.52 ± 6.62 20.99 ± 6.18 13.63 ± 5.99 < 0.001
Emotional IVI score 8.82 ± 3.24 10.75 ± 2.46 9.06 ± 3.11 10.63 ± 3.05 7.22 ± 2.98 < 0.001
Rasch guided SF-36 physical functioning score 19.98 ± 7.58 23.21 ± 5.73 19.76 ± 8.02 16.93 ± 7.35 20.29 ± 7.58 0.141
Rasch guided SF-36 mental health score 14.48 ± 6.19 16.77 ± 6.04 13.91 ± 5.67 14.30 ± 5.93 14.35 ± 6.69 0.478
  1. SD = Standard deviation; CVCs = cardiovascular complications; VI = Vision impairment; BCVA = Best corrected distance visual acuity. *ANOVA, testing for difference between all groups.